+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Bioanalysis & DMPK Studies, Toxicology Testing), By Model Type, By Technology, By End-use, By State, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 80 Pages
  • April 2024
  • Region: United States
  • Grand View Research
  • ID: 5967374
Description Jump to:

U.S. Preclinical CRO Market Growth & Trends

The U.S. preclinical CRO market size is anticipated to reach USD 5.9 billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030. Factors such as the increasing expenditure on R&D activities and the focus of pharmaceutical companies on cost reduction are driving the market growth.

There has been a significant increase in the R&D budget for early-stage and late-stage drug development processes, which is expected to contribute to market growth. The rising biopharmaceutical failure rates and the costs they entail have also driven the biopharmaceutical & life sciences companies to focus more on the early stage of the drug discovery and development process. This is likely to propel the growth of the market for preclinical CRO.

The increasing cases of Alzheimer's disease globally, demand for cutting-edge gene therapies, incidence of neurodegenerative diseases, and high prevalence of genetic disorders are some of the factors promoting the growth of advanced therapies. A substantial number of major & small biotechnology companies are driving innovation in this field in terms of technology & manufacturing capabilities, thereby offering commercial opportunities for market expansion.

Furthermore, the recent approval of new products has accelerated R&D activities. For instance, in December 2023, the FDA approved two groundbreaking treatments-Casgevy and Lyfgenia. These treatments mark a significant milestone as the first cell-based gene therapies suggested for the treatment of sickle cell disease in patients aged 12 and older.

U.S. Preclinical CRO Market Report Highlights

  • Discovery research dominated the service segment with 29.6% share in 2023, owing to the rising trend of outsourcing research in the biotechnology and pharmaceutical companies to accelerate drug discovery and reduce cost.
  • The bioanalysis and DMPK studies segment is expected to witness the fastest CAGR over the forecast period, owing to widescale applications of CROs in bioanalysis studies.
  • Increasing demand for personalized medicine and advanced therapeutics, life science companies focusing on their core competencies, and the increasing trend of outsourcing are expected to drive the market growth over the forecast period.
  • In August 2022, WuXi STA announced its new 190-acre pharmaceutical manufacturing campus in the U.S. This site would be its second facility, offering expanded capacity and flexibility to meet customers’ needs in the U.S. and across the globe.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Services
1.2.2. Model Type
1.2.3. Technology
1.2.4. End-use
1.2.5. States
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal Database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Services outlook
2.2.2. Model Type outlook
2.2.3. Technology outlook
2.2.4. End-use outlook
2.2.5. States outlook
2.3. Competitive Insights
Chapter 3. U.S. Preclinical CRO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising outsourcing trend
3.2.1.2. Increasing focus of life science companies on their core competencies
3.2.1.3. Increasing demand of personalized medicine and advanced therapeutics
3.2.1.4. Increasing pharmaceutical R&D investments
3.2.2. Market restraint analysis
3.2.2.1. Monitoring issues and lack of standardization
3.2.2.2. Managing relationships
3.3. U.S. Preclinical CRO Market Analysis Tools
3.3.1. Industry analysis - Porter's
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Preclinical CRO Market: Services Estimates & Trend Analysis
4.1. Services Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Preclinical CRO Market by Services Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Bioanalysis and DMPK studies
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. In vitro ADME
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. In-vivo PK
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Toxicology testing
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. GLP
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Non-GLP
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Compound management
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.2. Process R&D
4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.3. Custom synthesis
4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.4. Others
4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Chemistry
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4.2. Medicinal chemistry
4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4.3. Computation chemistry
4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Safety pharmacology
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Discovery research
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6.2. Target identification & screening
4.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6.3. Target validation & functional informatics
4.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6.4. Lead identification & candidate optimization
4.4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6.5. Preclinical development
4.4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6.6. Other associated workflow
4.4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.7. Others
4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Preclinical CRO Market: Model Type Estimates & Trend Analysis
5.1. Model Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Preclinical CRO Market by Model Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Small animal models
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. Mice
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Rats
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.4. Rabbits
5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.5. Others
5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Large animal models
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Pig
5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.3. Others
5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Organoid models
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Cell culture models
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Others
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Preclinical CRO Market: Technology Estimates & Trend Analysis
6.1. Technology Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Preclinical CRO Market by Technology Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. In vivo studies
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. In vitro studies
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Ex vivo studies
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Imaging technologies
6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4.2. Ultrasound imaging
6.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4.3. MRI imaging
6.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4.4. CT imaging
6.4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4.5. Radionuclide imaging
6.4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4.6. Other imaging technologies
6.4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Other technologies
6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Preclinical CRO Market: End-use Estimates & Trend Analysis
7.1. End-use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. U.S. Preclinical CRO Market by End-use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Biopharmaceutical companies
7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
7.4.2. Research and academic institutes
7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. Medical device companies
7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company heat map analysis, 2023
8.4. Company Profiles
8.4.1. Laboratory Corporation of America
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Lonza
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. WuXi AppTec, Inc.
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Eurofins Scientific SE
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Intertek Group plc
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Medpace Holdings, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Charles River Laboratories International, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. SGA SA
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific, Inc.)
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. ICON plc
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. CROWN bioscience
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. preclinical CRO market, by services, 2018 - 2030 (USD Million)
Table 4 U.S. preclinical CRO market, by bioanalysis and DMK studies, 2018 - 2030 (USD Million)
Table 5 U.S. preclinical CRO market, by toxicology testing, 2018 - 2030 (USD Million)
Table 6 U.S. preclinical CRO market, by compound management, 2018 - 2030 (USD Million)
Table 7 U.S. preclinical CRO market, by chemistry, 2018 - 2030 (USD Million)
Table 8 U.S. preclinical CRO market, by safety pharmacology, 2018 - 2030 (USD Million)
Table 9 U.S. preclinical CRO market, by discovery research, 2018 - 2030 (USD Million)
Table 10 U.S. preclinical CRO market, by others, 2018 - 2030 (USD Million)
Table 11 U.S. preclinical CRO market, by model type, 2018 - 2030 (USD Million)
Table 12 U.S. preclinical CRO market, by small animal models, 2018 - 2030 (USD Million)
Table 13 U.S. preclinical CRO market, by large animal models, 2018 - 2030 (USD Million)
Table 14 U.S. preclinical CRO market, by organoid models, 2018 - 2030 (USD Million)
Table 15 U.S. preclinical CRO market, by cell culture models, 2018 - 2030 (USD Million)
Table 16 U.S. preclinical CRO market, by others, 2018 - 2030 (USD Million)
Table 17 U.S. preclinical CRO market, by technology, 2018 - 2030 (USD Million)
Table 18 U.S. preclinical CRO market, by in vivo studies, 2018 - 2030 (USD Million)
Table 19 U.S. preclinical CRO market, by in vitro studies, 2018 - 2030 (USD Million)
Table 20 U.S. preclinical CRO market, by ex vivo studies, 2018 - 2030 (USD Million)
Table 21 U.S. preclinical CRO market, by imaging technologies, 2018 - 2030 (USD Million)
Table 22 U.S. preclinical CRO market, by other technologies, 2018 - 2030 (USD Million)
Table 23 U.S. preclinical CRO market, by end-use, 2018 - 2030 (USD Million)
Table 24 U.S. preclinical CRO market, by biopharmaceutical companies, 2018 - 2030 (USD Million)
Table 25 U.S. preclinical CRO market, by research and academic institutes, 2018 - 2030 (USD Million)
Table 26 U.S. preclinical CRO market, by medical device companies, 2018 - 2030 (USD Million)
Table 27 U.S. preclinical CRO market, by states, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. preclinical CRO market: market outlook
Fig. 9 U.S. preclinical CRO competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. preclinical CRO market driver impact
Fig. 14 U.S. preclinical CRO market restraint impact
Fig. 15 U.S. preclinical CRO market: Services movement analysis
Fig. 16 U.S. preclinical CRO market: Services outlook and key takeaways
Fig. 17 Bioanalysis and DMPK studies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 In vitro ADME market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 In vivo PK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Toxicology testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 GLP market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Non-GLP market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Compound management market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Process R&D market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Custom synthesis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Medicinal chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Computation chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Safety pharmacology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Discovery research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Target identification & screening market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Target validation & functional informatics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Lead identification & candidate optimization market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Preclinical development market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Other associated workflow market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 U.S. preclinical CRO market: Model type movement analysis
Fig. 39 U.S. preclinical CRO market: Model type outlook and key takeaways
Fig. 40 Small animal models market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Mice model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Rats model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Rabbits model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Other model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Large animal models market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Pigs model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Other model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Organoid models market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Cell culture models market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 U.S. preclinical CRO market: Technology movement analysis
Fig. 52 U.S. preclinical CRO market: Technology outlook and key takeaways
Fig. 53 In vivo studies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 In vitro studies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Ex vivo market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Imaging technologies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Ultrasound imaging market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 MRI imaging market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 CT imaging market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Radionuclide imaging market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Other imaging technologies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Other technologies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 U.S. preclinical CRO market: End-use movement analysis
Fig. 64 U.S. preclinical CRO market: End-use outlook and key takeaways
Fig. 65 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

  • Laboratory Corporation of America
  • Lonza
  • WuXi AppTec, Inc.
  • Eurofins Scientific SE
  • Intertek Group plc
  • Medpace Holdings, Inc.
  • Charles River Laboratories International, Inc.
  • SGA SA
  • Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific, Inc.)
  • ICON plc
  • CROWN bioscience

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages80
PublishedApril 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 3.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.9 Billion
Compound Annual Growth Rate7.1%
Regions CoveredUnited States
No. of Companies Mentioned11

Related Topics

Related Reports

In Vivo CRO Market Size, Share & Trends Analysis Report by Model Type (Rodent Based, Non-rodent Based), Modality (Small Molecule, Large Molecule), Indication, GLP Type (Non GLP, GLP Toxicology), Region, and Segment Forecasts, 2024-2030 - Product Image

In Vivo CRO Market Size, Share & Trends Analysis Report by Model Type (Rodent Based, Non-rodent Based), Modality (Small Molecule, Large Molecule), Indication, GLP Type (Non GLP, GLP Toxicology), Region, and Segment Forecasts, 2024-2030

  • Report
  • 257 Pages
  • Global
From
Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Preclinical CRO Market by Services, Application, End-User - Global Forecast 2025-2030 - Product Image

Preclinical CRO Market by Services, Application, End-User - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Preclinical Imaging Market by Product, Application, End-User - Global Forecast 2025-2030 - Product Image

Preclinical Imaging Market by Product, Application, End-User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions - Product Image

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions

  • Report
  • 343 Pages
  • Global
From

About the Preclinical CRO Market

The Preclinical CRO market is a subset of the Drug Discovery industry, focusing on the preclinical stages of drug development. Preclinical CROs provide services such as drug safety testing, pharmacology studies, and toxicology studies. These services are used to assess the safety and efficacy of potential drugs before they are tested in humans. Preclinical CROs also provide services such as drug metabolism and pharmacokinetics, which are used to understand how a drug is absorbed, distributed, metabolized, and eliminated in the body. Preclinical CROs are an important part of the drug discovery process, as they provide the data needed to move a drug candidate forward in the development process. Preclinical CROs are also used to reduce the cost and time associated with drug development, as they can provide the data needed to make decisions quickly and efficiently. Some companies in the Preclinical CRO market include Charles River Laboratories, WuXi AppTec, Covance, PRA Health Sciences, and Envigo. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.